Results 31 to 40 of about 18,389 (235)

Characteristics of patients by gender at initiation of LVAD evaluation (Baseline) and by LVAD implantation status at 6 months.

, 2023
Characteristics of patients by gender at initiation of LVAD evaluation (Baseline) and by LVAD implantation status at 6 months.
Jocelyn S. Thompson (5320649), Tracy Makuvire (17283611), Muhammad H. Maqsood (17283608), Colleen K. McIlvennan (5320655), Larry A. Allen (5320652), Joseph M. Kim (17283605), Daniel D. Matlock (5320646), Haider J. Warraich (9212464)   +7 more
core   +1 more source

The Effect of Left Ventricular Assist Devices (LVAD) on Pulmonary Hypertension in End-Stage Heart Failure.

, 2021
Despite the increasing prevalence of advanced heart failure, transplantation rates have remained stable in Canada due to limited organ availability. Consequently, the number of implanted left ventricular assist devices (LVAD) and average time on device ...
Tremblay, Philippe
core  

Similar changes in miR expression in pulsatile flow (pf-LVAD) and continuous flow LVAD (cf-LVAD).

, 2015
The alteration in miR-expression in myocardial tissue of both pf-LVAD (n = 17) and cf-LVAD (n = 17) patients. miR-129* (a) and miR-146a (b) are up-regulated in post-LVAD in comparison to pre-LVAD, whereas miR- 155 (c), miR-221 (d) and miR-222 (e) are ...
Nicolaas de Jonge (551513), Ankie J. P. van Geffen (802772), Bjorn Winkens (474672), Erica Siera (802775), Manon M. H. Huibers (802773), Roel A. de Weger (551515), Paula A. da Costa Martins (318745), Petra van der Weide (802774), Pieter A. Doevendans (137859), Joyce van Kuik (802771), Sjoukje I. Lok (383140)   +10 more
core   +1 more source

Patient characteristics HTX and LVAD patients.

, 2022
Patient characteristics HTX and LVAD patients.
Sebastian Roth (13173045), Ragnar Huhn (777631), Markus W. Hollmann (9727530), René M’Pembele (13173042), Michiel Morshuis (3279255), Thomas Bitter (4389781), Giovanna Lurati Buse (13961330), Henrik Fox (8385882)   +7 more
core   +1 more source

Baseline demographics of the patients supported with a pulsatile flow LVAD (pf-LVAD) and continuous flow LVAD (cf-LVAD) (validation).

, 2015
HF, heart failure; CVA, cerebrovascular accident; TIA, transient ischemic attack; NYHA, New York Heart Association; DCM, dilated cardiomyopathy; CRTD, cardiac resynchronization therapy defibrillator; ICD, implantable cardioverter defibrillator ...
Nicolaas de Jonge (551513), Ankie J. P. van Geffen (802772), Bjorn Winkens (474672), Erica Siera (802775), Manon M. H. Huibers (802773), Roel A. de Weger (551515), Paula A. da Costa Martins (318745), Petra van der Weide (802774), Pieter A. Doevendans (137859), Joyce van Kuik (802771), Sjoukje I. Lok (383140)   +10 more
core   +1 more source

Heart phantom with electrical properties of heart muscle tissue

Current Directions in Biomedical Engineering, 2018
The weakened heart is supported by a left ventricular assist device (LVAD) to supply the heart muscle with oxygenated blood. In case the heart muscle recovers during LVAD therapy, the patient has to be weaned from the device.
Korn Leonie, Lyra Simon, Rüschen Daniel, Pugovkin Alexander, Telyshev Dmitry, Leonhardt Steffen, Walter Marian   +6 more
doaj   +1 more source

Heart-Failing Jehovah's Witness Patient Successfully Treated by Minimally Invasive LVAD Implantation without Any Blood Transfusions

The Thoracic & Cardiovascular Surgeon Reports, 2015
Left ventricular assist device (LVAD) implantation without the use of any blood products is considered as a challenge. We present a 48-year-old patient (175 cm, 75 kg, body mass index 24.5 kg/m2) who was admitted to our clinic due to end-stage heart ...
Jasmin S. Hanke, Murat Avsar, Axel Haverich, Jan D. Schmitto   +3 more
doaj   +1 more source

Mechanistic assessment and ablation of left ventricular assist device related ventricular tachycardia in patients with severe heart failure

Frontiers in Physiology, 2023
Aims: Left-ventricular-assist-devices (lvad) are an established treatment for patients with severe heart failure with reduced ejection fraction (HF) and reduce mortality.
Felix Hohendanner, Felix Hohendanner, Felix Hohendanner, Matthias Bock, Julian Keznickl-Pulst, Vesna Furundzija, Vesna Furundzija, Sebastian Scholz, Doreen Schöppenthau, Doreen Schöppenthau, Yuriy Hrytsyna, Yuriy Hrytsyna, Volkmar Falk, Volkmar Falk, Volkmar Falk, Volkmar Falk, Burkert Pieske, Gerhard Hindricks, Gerhard Hindricks, Evgenij Potapov, Evgenij Potapov, Jin-Hong Gerds-Li, Jin-Hong Gerds-Li   +22 more
doaj   +1 more source

Silk Fibroin for Cardiovascular Medical Devices: Review of Material Properties, Applications, and Clinical Potential

Advanced NanoBiomed Research, EarlyView.
Silk fibroin is an attractive natural biomaterial that can be engineered into diverse cardiovascular constructs, including vascular grafts, cardiac patches, heart valves, and stent coatings. Its tunable biological and mechanical properties have driven substantial preclinical progress; however, widespread clinical translation in cardiovascular ...
Mahsa Haghighattalab, Matt Govendir, Kristina Andelovic, Zachary Och, Fatemeh Karimi, Munira Xaymardan, Tomasz Jungst, Jelena Rnjak‐Kovacina, Nona Farbehi   +8 more
wiley   +1 more source

Changes in eligibility for a subcutaneous cardioverter-defibrillator after implantation of a left ventricular assist device-A prospective analysis.

PLoS ONE, 2023
BackgroundThe number of left ventricular assist devices (LVADs) implanted in patients with end-stage heart failure is increasing. In this patient cohort, subcutaneous implantable cardioverter defibrillators (S-ICDs) could be a promising alternative to ...
Christos Zormpas, Johanna Mueller-Leisse, Stephan Hohmann, Jörg Eiringhaus, Henrike Aenne Katrin Hillmann, Jan D Schmitto, Christian Veltmann, David Duncker   +7 more
doaj   +1 more source